FDA Grants Priority Review to Bristol Myers Myeloma Drug Iberdomide

The U.S. Food and Drug Administration has accepted Bristol Myers Squibb’s application for iberdomide, granting it priority review for the treatment of relapsed or refractory multiple myeloma. The decision positions the therapy as a potential first-in-class treatment for patients whose blood cancer has returned or failed to respond to existing standard-of-care regimens.

February 17, 2026, 04:34 PM 0 0

FDA Grants Priority Review to Bristol Myers Myeloma Drug Iberdomide

The Princeton, N.J.-based pharmaceutical giant confirmed that the FDA has set a target action date of August 17 for its decision. Priority review status is reserved for therapies that offer significant improvements over current medical options, effectively accelerating the regulatory timeline for drugs targeting serious conditions.

A New Class of Therapy

Iberdomide represents a shift in oncology research as part of a novel class of medicines known as cereblon E3 ligase modulators (CELMoDs). If approved, the drug would become the first CELMoD agent on the U.S. market. According to Bristol Myers, the treatment is designed to be used in combination with standard therapies to address the high unmet need in the multiple myeloma patient population.

Multiple myeloma remains a challenging blood cancer characterized by frequent relapses. The company’s application focuses on patients with relapsed or refractory disease, a stage where treatment options often become limited. The clinical development of iberdomide underscores the industry's broader push toward protein degradation technologies to combat resistant tumors.

When reusing this material a link to Money Talk is required.